Friday, July 10, 2026

Drug profile · INN

metreleptin

metreleptin (MYALEPTA) is a leptin receptor agonist. Route of administration: injection. Current US regulatory status: approved.

FDA: approved EMA: approved PMDA: approved Alimentary tract and metabolism (A16) A16AA
US status approved
Patents linked 0
Pipeline programs 1
News articles 0
Drug details — metreleptin
US status
approved
Class
Alimentary tract and metabolism (A16)
Route
INJECTION
Patents
0
Programs
1
Data quality
0.84

Quick answer

metreleptin (MYALEPTA) is a leptin receptor agonist. Route of administration: injection. Current US regulatory status: approved.

Key facts

INN metreleptin
Brand MYALEPTA
Mechanism Leptin receptor agonist
Target Leptin receptor
Therapeutic class Alimentary tract and metabolism (A16)
Route INJECTION
Formulation INJECTABLE
ATC code A16AA

Mechanism of action

Leptin receptor agonist

Primary target: Leptin receptor

Approval history

Authority Status Date
FDA approved
EMA approved
PMDA approved

Pipeline programs

  1. Pramlintide+Metreleptin Phase 2 · Takeda · Obesity

Related & competitor drugs

  1. agalsidase alfa Alimentary tract and metabolism (A16)
  2. alogliptin Alimentary tract and metabolism (A10)
  3. alogliptin benzoate Alimentary tract and metabolism (A10)
  4. aprepitant Alimentary tract and metabolism (A04)
  5. budesonide Alimentary tract and metabolism (A07)
  6. canagliflozin Alimentary tract and metabolism (A10)

Frequently asked questions

What is metreleptin?

metreleptin (MYALEPTA) is a leptin receptor agonist. Route of administration: injection. Current US regulatory status: approved.

What is the brand name for metreleptin?

MYALEPTA is a marketed brand name for metreleptin. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of metreleptin?

metreleptin has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.